The complex between tPA and PAI-1: Risk factor for myocardial infarction as studied in the SHEEP project

Thrombosis Research

Volumn 116, Issue 3, 2005, Pages 223-232

  Nordenhem, Arvid ^a,d   Leander, Karin ^b   Hallqvist, Johan ^b,c   De Faire, Ulf ^a,b   Sten Linder, Margareta ^a   Wiman, Björn ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c STOCKHOLM COUNTY COUNCIL   (Sweden)

^d Pfizer AB   (Sweden)

Author keywords

Myocardial infarction; PAI 1; Risk marker; tPA

Indexed keywords

APOLIPOPROTEIN B; BIOLOGICAL MARKER; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL RESEARCH; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SAMPLE SIZE; SEX RATIO; SMOKING; SURVIVAL RATE; WAIST CIRCUMFERENCE;

CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; RISK FACTORS; SMOKING; SWEDEN; TISSUE DISTRIBUTION; TISSUE PLASMINOGEN ACTIVATOR;

EID: 20144362593     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.12.007     Document Type: Article

References (22)

1. A. Hamsten, U. de Faire, G. Walldius, G. Dahlén, A. Szamosi, and C. Landou Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction Lancet 2 1987 3 9
2. M. Cortellaro for the PLAT Group Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in artherosclerotic patients-a case-control study Arterioscler. Thromb. 13 1993 1412 1417
3. J.H. Jansson, B.O. Olofsson, and T.K. Nilsson Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7 year follow-up Circulation 88 1993 2030 2034
4. I. Juhan-Vague, S.D. Pyke, M.C. Alessi, J. Jespersen, F. Haverkate, and S.G. Thompson Fibrinolytic factors the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European concerted action on thrombosis and disabilities Circulation 94 1996 2057 2063
5. C. Held, P. Hjelmdahl, N. Rehnqvist, H. Wallén, I. Björkander, and S. Eriksson Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol Circulation 95 1997 2380 2386
6. A.M. Thogersen, J.H. Jansson, K. Boman, T.K. Nilsson, L. Weinehall, and F. Huhtasaari High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor Circulation 98 1998 2241 2247
7. A. Hamsten, B. Wiman, U. de Faire, and M. Blombäck Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction N. Engl. J. Med. 313 1985 1557 1563
8. K. Leander, B. Wiman, J. Hallqvist, M. Sten-Linder, and U. de Faire PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of non-fatal myocardial infarction: results from the Stockholm Heart Epidemiology Program (SHEEP) Thromb. Haemost. 89 2003 1064 1071
9. J.H. Jansson, T.K. Nilsson, and B.O. Olofsson Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris Eur. Heart J. 12 1991 157 161
10. P.M. Ridker, P.E. Vaughan, M.J. Stampfer, J.E. Manson, and C.H. Hennehens Endogenous tissue-type plasminogen activator and risk of myocardial infarction Lancet 341 1993 1165 1168
11. B. Wiman, T. Andersson, J. Hallqvist, C. Reuterwall, A. Ahlbom, and U. de Faire Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study Arterioscler. Thromb. Vasc. Biol. 20 2000 2019 2023
12. A. Nordenhem, and B. Wiman Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes Scand. J. Clin. Lab. Invest. 58 1998 475 484
13. C. Reuterwall, J. Hallqvist, A. Ahlbom, U. de Faire, F. Diderichsen, and C. Hogstedt Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the SHEEP study J. Intern. Med. 246 1999 161 174
14. SAS procedures guides [computer program]. SAS Institute 6.11. Cary, N.C.; 1990.
15. K.J. Rothman, and S. Greenland Modern Epidemiology 2nd ed. 1998 Lippincott-Raven Philadelphia
16. Lundberg, M, Fredlund P, Hallqvist J, Diderichsen F. A SAS program calculating three measures of interaction with confidence interval. Epidemiology 1006;7:655-656.
17. I. Juhan-Vague, M.C. Alessi, and P. Vague Increased plasma plasminogen activator inhibitor-1 levels. A possible link between insulin resistance and atherothrombosis Diabetologia 34 1991 457 462
18. I. Juhan-Vague, P. Vague, M. Alessi, C. Badier, J. Valadier, and M. Aillaud Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1 Diabetes Metab. 13 1987 331 336
19. I. Juhan-Vague, S.G. Thompson, J. Jespersen On behalf of the ECAT Angina Pectoris Study Group Involvement of the hemostatic system in the insulin resistance syndrome, a study of 15000 patients with angina pectoris Arterioscler. Thromb. 13 1993 1865 1873
20. K. Landin, L. Tengborn, and U. Smith Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease J. Int. Med. 227 1990 273 278
21. K. Landin, L. Stiegendal, E. Eriksson, M. Krotkiewski, B. Risberg, and L. Tengborn Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1 Metabolism 10 1990 1044 1048
22. I. Juan-Vague, M. Alessi, and P. Morange Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity Ann. Med. 32 2000 78 84